SGLT

Sodium-dependent glucose cotransporters

SGLTs (Sodium-dependent glucose cotransporters) are a family of glucose transporters and contribute to glucose reabsorption. The two most well-known members of SGLT family are SGLT1 and SGLT2, which are members of the SLC5A gene family. The two transporters are of primary importance for glucose homeostasis by absorbing glucose from the diet in the small intestine (via SGLT1) and by reabsorbing the filtered glucose in the tubular system of the kidney (primarily SGLT2; to smaller extent via SGLT1); the latter process returns glucose into the blood stream and prevents urinary glucose loss. SGLT1 and SGLT2 have been proposed as a novel therapeutic strategy for diabetes and cardiomyopathy.

SGLT Inhibitors

Canagliflozin
(JNJ 28431754) Cat. No.: HY-10451

Canagliflozin (JNJ 28431754) is a selective **SGLT2** inhibitor with **IC_{50}**s of 2 nM, 3.7 nM, and 4.4 nM for mSGLT2, rSGLT2, and hSGLT2 in CHOK cells, respectively.



Purity: 99.66%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Canagliflozin hemihydrate
(JNJ 28431754 hemihydrate) Cat. No.: HY-I0383

Canagliflozin hemihydrate (JNJ28431754 hemihydrate) is a selective **SGLT2** inhibitor with **IC_{50}**s of 2 nM, 3.7 nM, and 4.4 nM for mSGLT2, rSGLT2, and hSGLT2 in CHOK cells, respectively.



Purity: 99.95%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Canagliflozin-d4
(JNJ 28431754-d4) Cat. No.: HY-10451S

Canagliflozin D4 is a deuterium labeled Canagliflozin. Canagliflozin is a selective **SGLT2** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Dapagliflozin
(BMS-512148) Cat. No.: HY-10450

Dapagliflozin (BMS-512148), a new type of drug used to treat diabetes mellitus (DM), is a competitive sodium/glucose cotransporter 2 (**SGLT2**) inhibitor, which results in excretion of glucose into the urine. Dapagliflozin induces **HIF1** expression and attenuates renal IR injury.



Purity: 99.87%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Dapagliflozin ((2S)-1,2-propanediol, hydrate)
(BMS-512148 (2S)-1,2-propanediol, hydrate) Cat. No.: HY-10450A

Dapagliflozin ((2S)-1,2-propanediol, hydrate) is the S-enantiomer of Dapagliflozin 1,2-propanediol, hydrate.



Purity: 99.99%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Dapagliflozin-d5
(BMS-512148-d5) Cat. No.: HY-10450S

Dapagliflozin D5 (BMS-512148 D5) is a deuterium labeled Dapagliflozin. Dapagliflozin is a competitive SGLT2 inhibitor.



Purity: 98.08%
Clinical Data: No Development Reported
Size: 1 mg

Empagliflozin
(BI 10773) Cat. No.: HY-15409

Empagliflozin (BI 107730 is a selective sodium glucose cotransporter-2 (**SGLT-2**) inhibitor with an **IC_{50}** of 3.1 nM for human SGLT-2.



Purity: 99.93%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Empagliflozin-d4
(BI 10773-d4) Cat. No.: HY-15409S

Empagliflozin-d4 is deuterium labeled Empagliflozin. Empagliflozin (BI 107730 is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor with an IC50 of 3.1 nM for human SGLT-2.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Enavogliflozin
(DWP-16001) Cat. No.: HY-109144

Enavogliflozin (DWP-16001), an antidiabetic agent, is an orally active, best-in-class and selective sodium-glucose cotransporter-2 (**SGLT-2**) inhibitor.



Purity: 98.01%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Ertugliflozin
(PF-04971729) Cat. No.: HY-15461

Ertugliflozin (PF-04971729) is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2), with an IC_{50} of 0.877 nM for h-SGLT2. Has the potential for the treatment of type 2 diabetes mellitus.



Purity: 99.64%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

Ertugliflozin L-pyroglutamic acid

(PF-04971729 L-pyroglutamic acid)

Cat. No.: HY-15461A

Ertugliflozin L-pyroglutamic acid (PF-04971729 L-pyroglutamic acid) is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2), with an IC_{50} of 0.877 nM for h-SGLT2. Has the potential for the treatment of type 2 diabetes mellitus.



Purity: 99.77%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

HSK0935

Cat. No.: HY-101782

HSK0935 is a potent, highly selective and orally available **SGLT2** inhibitor with an **IC_{50}** of 1.3 nM. Antihyperglycemic activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ipragliflozin

(ASP1941)

Cat. No.: HY-14894

Ipragliflozin (ASP1941) is an orally active and selective **SGLT2** inhibitor with **IC_{50}**s of 7.38 and 1876 nM, 6.73 and 1166 nM, 5.64 and 1380 nM for human SGLT2 and SGLT1, rat SGLT2 and SGLT1, mouse SGLT2 and SGLT1, respectively. Antidiabetic agent.



Purity: 99.86%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Ipragliflozin (L-Proline)

Cat. No.: HY-14894A

Ipragliflozin (L-Proline) is a highly potent and selective **SGLT2** inhibitor with an **IC_{50}** of 2.8 nM; little and NO potency for SGLT1/3/4/5/6.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Ipragliflozin-d5

(ASP1941-d5)

Cat. No.: HY-14894S

Ipragliflozin-d5 (ASP1941-d5) is the deuterium labeled Ipragliflozin.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KGA-2727

Cat. No.: HY-123797

KGA-2727 is a first selective, high-affinity and orally active **SGLT1** inhibitor with **K_i**s of 97.4 nM and 43.5 nM for **human** and **rat SGLT1**, respectively. The selectivity ratios (**K_i** for SGLT2/**K_i** for **SGLT1**) of KGA-2727 are 140 (human) and 390 (rat). KGA-2727 has antidiabetic efficacy.



Purity: 99.04%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Kushenol K

Cat. No.: HY-117010

Kushenol K, a flavonoid antioxidant isolated from the roots of Sophora flavescens. Kushenol K is a **cytochrome P-450 3A4 (CYP3A4)** inhibitor with a **K_i** value of 1.35 μM. Kushenol K shows weak antiviral activity against **HSV-2** (**EC_{50}** of 147 μM).



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Licogliflozin

(LIK066)

Cat. No.: HY-109092

Licogliflozin is a sodium glucose cotransporter (**SGLT1** and **SGLT2**) inhibitor.



Purity: 98.20%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Luseogliflozin hydrate

(TS 071 hydrate)

Cat. No.: HY-10449A

Luseogliflozin (TS 071) hydrate is a selective potent and orally active second-generation sodium-glucose co-transporter 2 (**SGLT2**) inhibitor with an IC_{50}of2.26 nM. Luseogliflozin hydrate can be used for the research of type 2 diabetes mellitus (T2DM).



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

LX2761

Cat. No.: HY-101122

LX2761 is chemically stable and potent inhibitor against **sodium-dependent glucose cotransporter 1 (SGLT1)** and **SGLT2** in vitro with **IC_{50}**s of 2.2 nM and 2.7nM for hSGLT1 and hSGLT2, but displays specific SGLT1 inhibition in the gastrointestinal (GI) tract.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mizagliflozin (DSP-3235 free base; KGA-3235 free base; GSK-1614235 free base)

Cat. No.: HY-17638

Mizagliflozin (DSP-3235 free base) is a potent, orally active and selective **SGLT1** inhibitor, with a K_i of 27 nM for human SGLT1. Mizagliflozin displays 303-fold selectivity over SGLT2.



Purity: 99.35%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Phloretin (NSC 407292; RJC 02792)

Cat. No.: HY-N0142

Phloretin (NSC 407292; RJC 02792) is a flavonoid extracted from Prunus mandshurica, has anti-inflammatory activities. Phloridzin is a specific, competitive and orally active inhibitor of **sodium/glucose cotransporters** in the intestine (SGLT1) and kidney (SGLT2).



Purity: 99.78%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 250 mg, 500 mg

Phlorizin (Floridzin; NSC 2833)

Cat. No.: HY-N0143

Phlorizin is a non-selective **SGLT** inhibitor with K_is of 300 and 39 nM for **hSGLT1** and **hSGLT2**, respectively. Phlorizin is also a **Na^+/K^+-ATPase** inhibitor.



Purity: 99.82%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Remogliflozin etabonate (GSK189075)

Cat. No.: HY-14945

Remogliflozin etabonate (GSK189075) is an orally active, selective and low-affinity **sodium glucose cotransporter (SGLT2)** inhibitor with K_i values of 1.95 μM, 2.14 μM, 43.1 μM, 8.57 μM for hSGLT2, rSGLT2, hSGLT1, rSGLT1, respectively.



Purity: 99.47%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SGL5213

Cat. No.: HY-114308

SGL5213 is a potent, oral active and low-absorbable **sodium-dependent glucose cotransporter 1 (SGLT1)** inhibitor, with IC_{50} values of 29 nM and 20 nM for hSGLT1 and hSGLT2, respectively. SGL5213 has potential to treat type 2 diabetes treatment.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SGLT inhibitor-1

Cat. No.: HY-112807

SGLT inhibitor-1 is a potent dual inhibitor of **sodium glucose co-transporter proteins (SGLTs)**, inhibits hSGLT1 and hSGLT2 with IC_{50}s of 43 nM and 9 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SGLT1/2-IN-1

Cat. No.: HY-138944

SGLT1/2-IN-1 is a dual SGLT1/SGLT2 inhibitor extract from WO2015032272A1, compound 2 .



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SGLT1/2-IN-2

Cat. No.: HY-145357

SGLT1/2-IN-2 demonstrates potent dual inhibitory activities (IC_{50} = 96 nM for SGLT1 and IC_{50} = 1.3 nM for SGLT2).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Sotagliflozin (LX-4211; LP-802034)

Cat. No.: HY-15516

Sotagliflozin (LX-4211) is a potent dual SGLT2/1 inhibitor. Antidiabetic agents.



Purity: 99.89%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

T-1095

Cat. No.: HY-106158

T-1095 is a selective and orally active **Na^+-glucose cotransporter (SGLT)** inhibitor with IC_{50}s of 22.8 μM and 2.3 μM for human SGLT1 and SGLT2, respectively. T-1095 can be used for diabetes research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tofogliflozin

(CSG452)

Cat. No.: HY-14902

Tofogliflozin(CSG-452) is a potent and highly specific sodium/glucose cotransporter 2(SGLT2) inhibitor with Ki values of 2.9, 14.9, and 6.4 nM for human, rat, and mouse SGLT2.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Tofogliflozin (hydrate)

(CSG-452 hydrate)

Cat. No.: HY-13413

Tofogliflozin hydrate (CSG-452 hydrate) is a potent and highly specific **sodium/glucose cotransporter 2 (SGLT2)** inhibitor with an IC_{50} of 2.9 nM and K_i values of 2.9 nM, 14.9 nM, and 6.4 nM for human, rat, and mouse **SGLT2**.



Purity: 98.85%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Trilobatin

Cat. No.: HY-N4100

Trilobatin, a natural sweetener derived from Lithocarpus polystachyus Rehd, Trilobatin is an **HIV-1** entry inhibitor targeting the HIV-1 Gp41 envelope. Neuroprotective effects.



Purity: 98.85%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL,

Velagliflozin

Cat. No.: HY-109018

Velagliflozin is an orally available sodium-glucose cotransporter 2 (**SGLT2**) inhibitor, with anti-diabetic activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg